NASDAQ:PXMD PaxMedica (PXMD) Stock Price, News & Analysis $0.0005 0.00 (0.00%) As of 09/23/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider TradesSEC Filings About PaxMedica Stock (NASDAQ:PXMD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PaxMedica alerts:Sign Up Key Stats Today's Range$0.0005▼$0.000550-Day Range N/A52-Week Range$0.00▼$0.02VolumeN/AAverage Volume4,577 shsMarket Capitalization$5.66 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview PaxMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and neurodevelopmental disorders. The company’s research centers on antipurinergic therapy, an approach intended to address biological pathways associated with conditions such as autism spectrum disorder. PaxMedica’s lead product candidate is PAX-101, an intravenous formulation of suramin. The company has investigated PAX-101 in clinical studies involving autism spectrum disorder and has also explored its potential use in other neurological conditions. Suramin has additionally been studied as a treatment for human African trypanosomiasis, commonly known as African sleeping sickness. Based in the United States, PaxMedica has focused primarily on advancing its development programs through clinical research and regulatory activities. The company’s programs and leadership have been associated with physician-scientist Howard Weiner, who has served in executive and board leadership roles. As a development-stage biotechnology company, PaxMedica’s products remain subject to clinical testing and regulatory review.AI Generated. May Contain Errors. Read More Receive PXMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PaxMedica and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PXMD Stock News HeadlinesPaxMedica, Inc. (PXMD) - Yahoo FinanceJuly 11, 2025 | nz.finance.yahoo.comStudy Links Iron Deficiency to Disturbed Sleep Among Autism, ADHD PatientsSeptember 23, 2024 | msn.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.September 24 at 1:00 AM | Porter & Company (Ad)BioMedNewsBreaks — PaxMedica Inc. (PXMD) Announces Immediate Exercise of Warrants to Total Approximately $884KSeptember 3, 2024 | msn.comYale Study Unravels Autism, Brain Growth PatternsSeptember 1, 2024 | msn.comPaxMedica, Inc.: PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness InfectionAugust 27, 2024 | finanznachrichten.dePaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101May 15, 2024 | globenewswire.comPXMD Stock Earnings: PaxMedica Misses EPS for Q1 2024May 13, 2024 | investorplace.comSee More Headlines PXMD Stock Analysis - Frequently Asked Questions How have PXMD shares performed this year? PaxMedica's stock was trading at $0.0001 at the beginning of the year. Since then, PXMD stock has increased by 400.0% and is now trading at $0.0005. When did PaxMedica's stock split? PaxMedica shares reverse split on Tuesday, October 31st 2023.The 1-17 reverse split was announced on Monday, October 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did PaxMedica IPO? PaxMedica (PXMD) raised $9 million in an initial public offering on Friday, August 26th 2022. The company issued 1,600,000 shares at $4.50-$6.50 per share. Craft Capital Management and R.F.Lafferty & Co. acted as the underwriters for the IPO. How do I buy shares of PaxMedica? Shares of PXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of PaxMedica own? Based on aggregate information from My MarketBeat watchlists, some other companies that PaxMedica investors own include Pfizer (PFE), PayPal (PYPL), Oracle (ORCL), Arista Networks (ANET), Avino Silver & Gold Mines (ASM) and Corbus Pharmaceuticals (CRBP). Company Calendar Today9/24/2026Next Earnings (Estimated)12/02/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PXMD CIK1811623 Webwww.paxmedica.com Phone914-987-2876FaxN/AEmployees6Year Founded2018Profitability EPS (Trailing Twelve Months)($6.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.29 million Net MarginsN/A Pretax MarginN/A Return on Equity-3,167.89% Return on Assets-560.35% Debt Debt-to-Equity RatioN/A Current Ratio0.38 Quick Ratio0.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book0.00Miscellaneous Outstanding Shares11,312,000Free Float11,199,000Market Cap$5.66 thousand OptionableNot Optionable Beta-0.99 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:PXMD) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...American Alternative | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredNASA's ISS Replacement Could Go to This Tiny Space FirmNASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to...Behind the Markets | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PaxMedica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PaxMedica With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
